» Articles » PMID: 21619920

Panax Notoginseng Saponins Inhibit Ischemia-induced Apoptosis by Activating PI3K/Akt Pathway in Cardiomyocytes

Overview
Date 2011 May 31
PMID 21619920
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Aim Of This Study: The panax notoginseng saponins (PNS) have been clinically used for the treatment of cardiovascular diseases and stroke in China. Evidences demonstrated that PNS could protect cardiomyocytes from injury induced by ischemia, but the underlying molecular mechanisms of this protective effect are still unclear. This study was aimed to investigate the protective effect and potential molecular mechanisms of PNS on apoptosis in H9c2 cells in vitro and rat myocardial ischemia injury model in vivo.

Materials And Methods: H9c2 cells subjected to serum, glucose and oxygen deprivation (SGOD) were used as in vitro models and SD rats subjected to left anterior descending (LAD) coronary artery ligation were used as in vivo models. The anti-apoptotic effect of PNS was evaluated by Annexin V/PI analysis or TUNEL assay. Mitochondrial membrane potential (Δψm) was detected by JC-1 analysis. The expression of Akt and phosphorylated Akt (p-Akt) were detected by western blot assay.

Results: PNS exhibited anti-apoptotic effect both in H9c2 cells and in ischemic myocardial tissues. However, the effect was blocked in vitro by LY294002, a specific PI3K inhibitor. The anti-apoptotic effect of PNS was mediated by stabilizing Δψm in H9c2 cells. Furthermore the indices of the left ventricular ejection fractions (EF), left ventricular fractional shortening (FS), left ventricular dimensions at end diastole (LVDd) and left ventricular dimensions at end systole (LVDs) suggested that PNS improved rats cardiac function. PNS significantly increased p-Akt both in H9c2 cells and in ischemic myocardial tissues and this effect was also blocked by LY294002 in H9c2 cells.

Conclusion: Results of this study suggested that PNS could protect myocardial cells from apoptosis induced by ischemia in both the in vitro and in vivo models through activating PI3K/Akt signaling pathway.

Citing Articles

Comparative efficacy of eight oral Chinese patent medicines for dilated cardiomyopathy with heart failure: a Bayesian network meta-analysis.

Tao S, Yu L, Li J, Shao M, Yang D, Wu J Syst Rev. 2024; 13(1):222.

PMID: 39217375 PMC: 11365150. DOI: 10.1186/s13643-024-02582-5.


Effect of adjuvant therapy with compound danshen drip pill on inflammatory factors and cardiac function after percutaneous coronary intervention for acute myocardial infarction: a systematic review and meta-analysis.

Fan G, Liu M, Song H, Wang Y Front Pharmacol. 2024; 15:1345897.

PMID: 38689665 PMC: 11058228. DOI: 10.3389/fphar.2024.1345897.


Efficacy and safety of saponin injection in the treatment of acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.

Chen P, Gao Z, Guo M, Pan D, Zhang H, Du J Front Pharmacol. 2024; 15:1353662.

PMID: 38576488 PMC: 10991745. DOI: 10.3389/fphar.2024.1353662.


Efficacy and safety of saponins (Xuesaitong) for patients with acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials.

Shi X, Feng L, Li Y, Qin M, Li T, Cheng Z Front Pharmacol. 2023; 14:1280559.

PMID: 37908976 PMC: 10614024. DOI: 10.3389/fphar.2023.1280559.


Compound Kushen injection attenuates angiotensin II‑mediated heart failure by inhibiting the PI3K/Akt pathway.

Wang W, Liu D, Yang L, Chen L, Miao M, Liu Y Int J Mol Med. 2023; 51(3).

PMID: 36734284 PMC: 9943540. DOI: 10.3892/ijmm.2023.5226.